The EuroSIDA study is a prospective observational cohort study of more than 22,000 patients followed in 100 hospitals in 35 European countries plus Israel and Argentina. The main objective of the study is to follow the long-term clinical prognosis for the general population of HIV-infected patients living in Europe and to assess the impact of antiretroviral drugs on the long-term prognosis for these patients. The EuroSIDA study was initiated in 1994 and continues to expand in multiple ways. Being an observational study, the type of data collected has diversified tremendously since the start, as advances in the medical management of HIV has allowed for HIV-infected patients to foresee a good life prognosis. Early in the study, EuroSIDA initiated a focus on reliably collecting data on end-organ diseases and non-AIDS cancers, and confounders relevant for predicting risk factors for their occurrence. Much of the work relating to predicting the risk of cardiovascular disease (including the design of the D:A:D Study ) was a result of this foresight. Subsequently, the study has expanded the scope of research focus to also address liver disease, renal disease, and non-AIDS defining cancers. 

The EuroSIDA study has published more than 270 peer-reviewed publications, based on EuroSIDA only data and in collaborations with others. More than 165,000 plasma samples are stored in a central repository and the database contains over 180,000 PYFU.

Primary research focus include:
  • Hepatitis
  • Biomarkers
  • Regional differences
  • Resistance
Principle Investigator: Gilles Wandeler